RCUS vs. SCHZ

In the year-to-date period, RCUS achieves a -40.03% return, which is significantly lower than SCHZ's 2.54% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arcus Biosciences, Inc. (RCUS) and Schwab U.S. Aggregate Bond ETF (SCHZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RCUS Sharpe Ratio is -0.65, which is lower than the SCHZ Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of RCUS and SCHZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

RCUS has not paid dividends to shareholders, while SCHZ's dividend yield for the trailing twelve months is around 4.03%.

The maximum RCUS drawdown since its inception was -85.83%, which is greater than SCHZ's maximum drawdown of -18.74%. Use the drawdown chart below to compare losses from any high point for RCUS and SCHZ.

Arcus Biosciences, Inc. (RCUS) has a higher volatility of 17.93% compared to Schwab U.S. Aggregate Bond ETF (SCHZ) at 1.45%. This indicates that RCUS's price experiences larger fluctuations and is considered to be riskier than SCHZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.